Soleno Therapeutics (SLNO) Gains from Investment Securities (2013 - 2026)
Soleno Therapeutics (SLNO) reported Gains from Investment Securities of $1000.0 for Q1 2026, down 72.22% year-over-year from $3600.0 in Q1 2025, and up 100.14% quarter-over-quarter from -$717000.0 in Q4 2025.
Soleno Therapeutics (SLNO) Gains from Investment Securities (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 14 years of Gains from Investment Securities data on file, last reported at $1000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $1000.0, down 72.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 67094.44% YoY), and the FY2025 annual result was $4.0 million, up 1.52% from the prior year.
- Gains from Investment Securities advanced to $1000.0 in Q1 2026 per SLNO's latest filing, from -$717000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $2.8 million in Q4 2024 and troughed at -$717000.0 in Q4 2025.
- A 5-year average of $507011.5 and a median of $219310.0 in 2022 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities sank 5600.0% in 2023, then surged 5254.55% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $1000.0 in 2022, then slumped by 5600.0% to -$55000.0 in 2023, then surged by 5254.55% to $2.8 million in 2024, then slumped by 125.29% to -$717000.0 in 2025, then soared by 100.14% to $1000.0 in 2026.
- Business Quant data shows SLNO's Gains from Investment Securities at $1000.0 in Q1 2026, -$717000.0 in Q4 2025, and $193168.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | -717,000.00 |
| Dec 31, 2025 | -717,000.00 |
| Sep 30, 2025 | 193,168.00 |
| Sep 30, 2025 | 193,168.00 |
| Jun 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 3,600.00 |
| Mar 31, 2025 | 3,600.00 |
| Dec 31, 2024 | 2.84 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 359,030.00 |
| Mar 31, 2024 | 359,030.00 |
| Dec 31, 2023 | -55,000.00 |
| Dec 31, 2023 | -55,000.00 |